

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07H 21/00, 1/08</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/00435</b> <b>(43) International Publication Date:</b> 8 January 1998 (08.01.98)
<b>(21) International Application Number:</b> PCT/US97/11496 <b>(22) International Filing Date:</b> 30 June 1997 (30.06.97)  <b>(30) Priority Data:</b> 60/021,195 3 July 1996 (03.07.96) US  <b>(71) Applicant (for all designated States except US):</b> PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; University Place, 124 Mount Auburn Street, Cambridge, MA 02138-5701 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VERDINE, Gregory, L. [US/US]; 91 Outlook Drive, Lexington, MA 02173 (US). MIN, Changhee [KR/KR]; Doongji Apartment 109-1404, Doonsan Dong, Suh Ku, Daejon 302-173 (KR).  <b>(74) Agent:</b> OYER, Timothy, J.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> OLIGONUCLEOTIDE LINKER AND TECHNIQUES INVOLVING IMMOBILIZED AND LINKED OLIGONUCLEOTIDES  <b>(57) Abstract</b>  A technique is provided for linking an oligonucleotide, such as a single strand of DNA, to another moiety or solid phase. An oligonucleotide is provided with a linking functionality that can be defined by six neighboring hystaminyal purines, which can be coordinated to a metal ion that also is coordinated by a chelating linked to a solid phase or other moiety. The invention finds particular use in resolution of one strand of DNA from its complement by providing the first strand with the linking functionality and passing the DNA across a metal affinity chromatography solid phase.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## **OLIGONUCLEOTIDE LINKER AND TECHNIQUES INVOLVING IMMOBILIZED AND LINKED OLIGONUCLEOTIDES**

### **Field of the Invention**

5           The present invention relates generally to the production of single-stranded DNA molecules, and more particularly to the production of single-stranded DNA using immobilized metal affinity chromatography.

### **Background of the Invention**

10           Many of the most widely employed operations in molecular biology hinge upon the use of single-stranded DNA as a probe or template. Whereas single strands of DNA containing up to approximately 100 residues can readily be produced by solid-phase synthesis, longer oligodeoxynucleotides typically must be generated through enzymatic methods such as the polymerase chain reaction (PCR). Because biochemical procedures for the synthesis of mixed-  
15   sequenc DNA yield double-stranded products, there exists a need for a method by which to resolve a desired strand from its complement. Such resolution is rendered difficult by the similarities in macroscopic physical properties such as size and charge of two complimentary strands, and by the requirement that resolution be carried out in the presence of strong denaturants such as urea or guanidinium hydrochloride.

20           Techniques exist for attaching a single biotin onto an oligonucleotide, then using a solid matrix at which is immobilized avidin or streptavidin, to immobilize the oligonucleotide. A problem with this approach is that the binding that is required for the technique to be effective depends upon proteins being properly folded. Therefore, the technique cannot be used under strong denaturing conditions. Also, if the technique is to be used to surface-immobilize a single  
25   DNA strand for surface plasmon resonance studies, the avidin/biotin combination adds enough mass to the surface that the technique, when used to detect binding of a single strand of DNA to the immobilized strand, can lack precision.

          It is, therefore, a object of the present invention to provide improved techniques for linking an oligonucleotide such as DNA, or a single strand of DNA, to another moiety or a  
30   surface, and to resolve a desired strand of DNA from its complement.

### **Summary of the Invention**

          The present invention provides a nucleotide coupled to a linking moiety that can

coordinate a metal ion, namely, a species having a formula  $L_n-N_y$ , where N represents the nucleotide and L represents the moiety which can coordinate a metal ion. n is at least 1, and y is at least 1. According to one embodiment  $N_y$  is DNA, and L can be histaminylpurine where n is approximately 6.

5 According to another aspect, the invention provides a species having a formula  $R-Ch-M-L_n-N_y$ . According to this aspect, R represents a chemical moiety that can be linked to a surface, or linked to a chemical or biological species. Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent, N represents a nucleotide, L represents a moiety that can coordinate a metal ion, and n and y each is at least 1.

10 The chelating agent is, according to one embodiment, a quadridentate chelating agent, for example nitrilotriacetic acid.

The invention also provides a single stranded oligonucleotide immobilized on a surface and free of hybridization to any complimentary strand that is also immobilized on the surface to the extent that the complimentary strand cannot be removed under conditions that cause  
15 denaturation of oligonucleotide strand from its complimentary strand. The single-stranded immobilized oligonucleotide also will withstand conditions, while remaining immobilized, harsher than 2 molar urea. The strand can be a strand of DNA.

According to another aspect the invention provides a method. The method involves providing first and second complementary strands of oligonucleotide, contacting a surface of a  
20 solid phase with the first and second strands, and allowing the first strand to be immobilized at the surface. The second strand is allowed to be carried away from the surface without immobilization at the surface. According to one embodiment, this aspect involves providing first and second complementary strands of DNA in a fluid medium, passing the fluid medium across a surface of a solid phase, and allowing the first strand to be immobilized at the surface while the  
25 second strand is allowed to be carried by the fluid medium away from the surface without immobilization.

The various aspects of the invention can be combined in a variety of ways. For example, the single stranded oligonucleotide immobilized on a surface and free of hybridization to any complimentary strand that is also immobilized on the surface to the extent that the  
30 complimentary strand cannot be removed under conditions that cause denaturation, can be immobilized via linkages such as  $L_n-N_y$  or  $R-Ch-M-L_n-N_y$ , above. Additionally, the methods can be practiced using any of the species that can facilitate immobilization of an oligonucleotide.

Other advantages, novel features, and objects of the invention will become apparent from the following detailed description of the invention when considered in conjunction with the accompanying drawings.

### **Brief Description of the Drawings**

Fig. 1 is a schematic representation of double-stranded DNA immobilized, via an attached linking moiety coordinated to a metal ion, to a solid phase surface;

Fig. 2 illustrates, schematically, primers and double-stranded PCR template used in one set of examples; and

Fig. 3 is a photocopy of a denaturing polyacrylamide gel electrophoresis analysis of DNA strand resolution using a technique of the present invention.


### **Detailed Description of the Invention**

Min, C., Cushing, T. Verdine, G., "Template-Directed Interference Footprinting of Protein-Adenine Contacts," *J. Am. Chem. Soc.* 1996, 118, 6116-6120; and Min, C. Verdine, G., "Immobilized Metal Affinity Chromatography of DNA," *Nucleic Acids Res.* 1996, 24, 3806-3810, both are incorporated herein by reference.

The present invention provides a linking functionality for attachment of an oligonucleotide to another moiety or to a surface of a solid phase, where solid phase is defined as any material insoluble in a medium used in conjunction with a procedure involving the oligonucleotide. The technique can be used, for example, to link an oligonucleotide to a solid phase surface such as a chromatography solid phase, or to a surface of a biosensor element such as a surface plasmon resonance (SPR) chip (for a discussion of SPR see, for example, Sternberg, et al., "Quantitative Determination of Surface Concentration of Protein with Surface Plasmon Resonance Using Radiolabeled Proteins", *Journal of Colloid and Interface Science*, 43:2 513-526, 1991, and references therein). The technique also can be used, for example, to link an oligonucleotide to a surface of a bead or plate used in a bioassay, to a label such as a fluorescent label, or another molecule or solid entity.

The invention involves providing a species having the generalized formula  $L_n-N_y$ , where  $N_y$  represents a natural or synthetic, single or multiple-strand oligonucleotide typified in DNA or a strand of DNA, and  $L_n$  represents a linking functionality where  $L$  represents a ligating moiety that can coordinate a metal ion, and  $n$  is at least 1, preferably at least 2, and more preferably at


least 5. According to preferred embodiments,  $n$  is from 2 to 10, and most preferably is about 6.  $L$  is a molecule that can be chemically attached to an oligonucleotide via, for example, the ester bond of the oligonucleotide backbone, and  $L_n$  has a generalized formula I. below.



where  $Z$  is an organic moiety and  $Y$  is a ligand having the ability to coordinate a metal ion,  $Z$  and  $Y$  together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence. Those of ordinary skill in the art can select appropriately  $Y$  and  $Z$  to meet the requirement of compatibility with an oligonucleotide sequence.  $Z$  and  $Y$  can be a single moiety in that a single organic moiety can provide functionality compatible with an oligonucleotide sequence and also coordinate a metal ion. Typically,  $Z$  is a hydrocarbon chain or a cyclic hydrocarbon group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon atoms. As used herein, "hydrocarbon" is meant to include alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkaryl, aralkyl, and the like. Hetero groups can include -O-, -CONH-, -CONHCO-, -NH-, -CSNH-, -CO-, -CS-, -S-, -SO-,  $-(\text{OCH}_2\text{CH}_2)_n\text{R}$  (where  $n=1-10$ ),  $-(\text{CF}_2)_n$  (where  $n=1-10$ ), olefins, and the like.

$Y$  (or  $Y$  and  $Z$  together) is a ligand that can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a metal affinity chromatography solid phase without complete coordination of the ion by the solid phase (see, for example, Hochuli et al., "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighboring Histidine Residues" *Journal of Chromatography*, 411 (1987) 177-184).  $Y$  can be as defined above for  $Z$ , and preferably includes groups such as -N-, alcohols, thiols, carboxylates (including carboxylic acid), and the like which can address a vacant coordination site on a metal ion. Cyclic and heterocyclic organic compounds including -N- such as imidazoles, phenanthroline, adenine, cytosine, and thymine are suitable. Additionally, amino acids satisfying these criteria, such as histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, and aspartate are suitable. Species such as hydroxamic acid also are suitable. In some cases, the above moieties can serve as  $Z$ , with a different one of the above or another moiety serving as  $Y$  and satisfying the criterion of coordination to a metal ion. For example, purine, thymine, adenine,

cytosine, or a combination could serve as Z, with another nucleic acid, amino acid, or nitrogen-containing cyclic, multi-cyclic, or heterocyclic compound serving as Y. Where, for example, purine, cytosine, or adenine are used as Z, the available  $-NH_2$ - group can be used to couple Y defined by, for example, histamine. According to one preferred embodiment, 6-histaminyl purine defines Y, and Z is a cyclic ether (II, below).



Species  $L_n-N_y$  finds use in conjunction with a metal ion partially coordinated by a chelating agent that is linked, or can be linked, to a moiety or surface of interest. That is, the species finds use in a combination of the formula:



where R represents a chemical or physical moiety, Ch represents a chelating agent that can coordinate a metal ion, and M represents a metal ion coordinated by the chelating agent. R can be a particulate species such as gold sol, a label such as a fluorescent label, a biological molecule of interest such as a binding partner for interaction with another species, a chromatography solid phase, or a linking or linkable moiety that can effect coupling of species III to any desired surface or species. The particular species or surface to which species III is coupled is not important, but the invention lies in the ability to coordinate  $N_y$  to R via  $L_n$ .

Co-pending, commonly-owned U.S. Patent Application Serial No. 08/312,388, filed September 26, 1994, now U.S. Patent No. 5,620,850, and incorporated herein by reference,

describes a variety of combinations of Ch and M suitable for use in the invention. In particular, the metal ion is preferably selected from those that have at least four coordination sites, preferably six coordination sites. A non-limiting list of metal ions suitable includes  $\text{Co}^{3+}$ ,  $\text{Cr}^{3+}$ ,  $\text{Hg}^{2+}$ ,  $\text{Pd}^{2+}$ ,  $\text{Pt}^{2+}$ ,  $\text{Pd}^{4+}$ ,  $\text{Pt}^{4+}$ ,  $\text{Rh}^{3+}$ ,  $\text{Ir}^{3+}$ ,  $\text{Ru}^{3+}$ ,  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$ ,  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Cd}^{2+}$ ,  $\text{Pb}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Fe}^{3+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Au}^{3+}$ ,  $\text{Au}^{+}$ ,  $\text{Ag}^{+}$ ,  $\text{Cu}^{+}$ ,  $\text{MO}_2^{2+}$ ,  $\text{Tl}^{3+}$ ,  $\text{Tl}^{+}$ ,  $\text{Bi}^{3+}$ ,  $\text{CH}_3\text{Hg}^{+}$ ,  $\text{Al}^{3+}$ ,  $\text{Ga}^{3+}$ ,  $\text{Ce}^{3+}$ ,  $\text{UO}_2^{2+}$ , and  $\text{La}^{3+}$ .

The chelating agent is preferably selected from bidentate, tridentate, and quadridentate, chelating agents, and is selected in conjunction with the metal ion so that when the chelating agent coordinates the metal ion, at least two free coordination sites of the metal remain. The chelating agent and metal are selected so that the chelating agent can coordinate the metal ion with a degree of stability great enough that the metal ion will remain immobilized at the surface by the chelating agent.

Additionally, the chelating agent is selected as one that has a chelating moiety and a non-chelating linker moiety, such that it can be covalently linked via its linker moiety to the moiety R while leaving the chelating moiety undisturbed by the covalent linkage and free to coordinate a metal ion. Alternatively, the chelating agent can be selected as one that can be modified via routine organic synthesis to include a non-chelating linker moiety, if such synthesis leaves undisturbed the chelating moiety. One of ordinary skill in the art will appreciate that the non-chelating linker moiety should provide functionality suitable for chemical linkage such as, for example, an amine, alcohol, carbamate, carboxylic acid, thiol, aldehyde, olefin, etc., for formation of an ester linkage, formation of an amide linkage, thiol displacement and thiol ether formation, and the like.

With the above considerations in mind, suitable chelating agents and corresponding metal ions can be selected by those of ordinary skill in the art. In accordance with such selection reference can be made to "Chelating Agents and Metal Chelates", Dwyer, F. P.; Mellor, D. P., Academic Press, and "Critical Stability Constants", Martell, A. E.; Smith, R. M., Plenum Press, New York. These works describe a variety of chelating agents, and discuss the stability of coordination between chelating agents and metal ions. Preferably, a chelating agent and metal ion is selected such that the dissociation constant of the combination in aqueous solution is better than  $10^{-10}$  M at physiological pH, that is, such that at least one half of the metal ions are coordinated by chelating agent at a concentration of  $10^{-10}$  M.

A non-limiting exemplary list of suitable chelating agents includes nitrilotriacetic acid, 2,2'-bis(salicylideneamino)-6,6'-dimethyldiphenyl, and 1,8-bis(4-pyridyl)-3,6-dithiaoctane.



As an example of one, preferred arrangement using species III, reference is made to Fig. 1, in which a species 25 linked to a solid phase surface includes an oligonucleotide, in particular DNA 10 including a first strand 12 and a second, complementary strand 14 including a linking functionality ( $L_n$ ) 16 defined by 6 histaminyl purines, two of which (18 and 20, respectively) are coordinated to a metal ion 22. Metal ion 22 also is coordinated by chelating agent 24 (a nitrilotriacetic acid derivative, as illustrated) which coordinates four of the six coordination sites of the metal ion, leaving two free coordination sites addressable by linking functionality 16. Chelating agent 24 is attached, via linker 26 (a hydrocarbon chain, as illustrated), to a surface 28 of a solid phase 30. Linkage of chelating agent 24 to surface 28 via linker 26 can be accomplished by any means such as covalent attachment, or the like.

A single-stranded oligonucleotide also is usefully immobilized as shown in FIG. 1 in accordance with the invention. According to one embodiment, linker 26 is selected as one that promotes formation of a self-assembled monolayer of a plurality of linkers 26 at surface 28, and linker 26 terminates at its end opposite the chelating agent in a functionality that is attracted to surface 28 and thereby promotes formation of a self-assembled monolayer. Such an arrangement of a metal-coordinating chelating agent immobilized at a surface as part of a self-assembled monolayer is described in commonly-owned co-pending U.S. patent application serial number 08/312,388, now U.S. Patent No. 5,620,850, referenced above. Self-assembled monolayer-forming species also are described in U.S. Patent No. 5,512,131, issued April 30, 1996 to Kumar and Whitesides, incorporated herein by reference. Where a self-assembled monolayer containing a chelating agent 24 is provided for use with species  $L_n$ - $N_y$  such as DNA 10 including linking functionality 16, it can be advantageous to form a self-assembled mixed monolayer (as defined in application serial number 08/312,388, and U.S. Patent No. 5,620,850 referenced above), that is, a heterogeneous self-assembled monolayer including an ordered assembly of at least another self-assembled monolayer-forming species other than species 25. A heterogeneous monolayer defined by less than about 50% of species 25 and greater than about 50% of another species such as one terminating in a moiety that does not interact with  $L_n$  or  $N_y$  can be formulated, as well as one with a ratio of less than about 30% species 25, or less than about 20% species 25, etc.

It is to be understood that coordination of linking functionality 16 to M may involve linkage via two neighboring ligating moieties L (H, for histaminyl purine, as illustrated in FIG. 1), or another arrangement. Additionally, linking functionality 16 may include neighboring ligating moieties L and/or ligating moieties L separated by one or more intermediate moieties

that do not have ligating capacity, so long as linking functionality 16 possesses the ability to coordinate free coordination sites at M.

Referring again to formula I, Y (and Y in combination with Z if Z has coordinating capacity) and n should be selected to provide the oligonucleotide with coordinating capacity  
5 sufficient to link the oligonucleotide to a metal ion to the extent that the oligonucleotide does not become detached from the metal ion during the course of a procedure involving the oligonucleotide coordinated to the metal ion so as, for example, to immobilize the oligonucleotide at a solid phase. Coordination should not, however, be so strong that  $L_n$  will compete with coordination of the metal ion by the chelating agent to the extent that the metal ion  
10 is stripped from the chelating agent (thus, e.g., stripped from a solid phase, label, or other moiety). For example, in most cases ligands such as ethylenediamine tetra acetic acid would be unsuitable. Those of ordinary skill in the art, with reference to "Chelating Agents and Metal Chelates," Dwyer, F.P.; Mellor, D.P., Academic Press, and "Critical Stability Constants", Martell, A.E.; Smith, R.M., Plenum Press, New York, can select a suitable group Y (and  
15 optionally Z) and the number of repeating units n for a particular metal ion including a particular number of free coordination sites.

In some cases it can be advantageous to test a particular  $L_n$ /M-Ch system to determine whether coordination will be sufficiently stable for use in the present invention, but will not be so stable that the metal ion is stripped from the chelating agent. For example, it is within the realm  
20 of routine experimentation to one of ordinary skill in the art to prepare a very simple polynucleotide containing as few as two nucleotides or up to approximately 6 or 8 with an attached linking functionality  $L_n$ , i.e., 3'-NNNNN- $L_n$ , where N is any nucleotide or a variety of nucleotides. The test oligonucleotide then can be labeled radioactively at the 5' end by mixing with  $T_4$  polynucleotide kinase, then with  $\gamma^{32}\text{P}$ -ATP. Then the oligonucleotide can be mixed with  
25 beads of resin containing immobilized, coordinated metal ion, the beads rinsed, and determination can be made as to whether radioactivity is present at the beads. If radioactivity is present, then the selection of L (i.e. Y or Y and R together) and n is appropriate to provide coordination capacity sufficient to immobilize the oligonucleotide, but not to the extent that the metal ion is stripped from the chelating agent.

30 If radioactivity is not present at the beads, then determination of whether the  $L_n$  combination results in insufficient coordination or coordination to an excessive extent such that metal ion is stripped can be made by subjecting the beads, and/or the solution used to flush the

beads, to ultraviolet spectroscopy or ICP to determine the location of the metal ion. These simple screening techniques can be performed by one of ordinary skill in the art without the necessity of synthesizing an entire oligonucleotide such as a DNA fragment useful in a particular procedure.

5 In some cases one would want to be able to separate the linker-nucleotide from the metal ion, as in elution from a column, and in some cases one would want essentially irreversible binding. Accordingly, as a second test, beads can be flushed with an eluting fluid such as 200mM imidazole and determination made as to whether the radioactivity is still present at the beads.

10 The present invention also represents an improvement over immobilization of single-stranded oligonucleotide at a surface via biotin/avidin or biotin/streptavidin linkage. That linkage will withstand conditions only up to 2 molar urea, or less. The present invention involves immobilization that withstands conditions harsher than 2 molar urea.

The function and advantage of these and other embodiments of the present invention will  
15 be more fully understood from the examples below. The following examples are intended to illustrate the benefits of the present invention, but do not exemplify the full scope of the invention.

#### Example 1: Synthesis Of A Nucleotide Including A Moiety That Can Coordinate A Metal Ion

20 A nucleotide that can coordinate a metal ion due to incorporation of a moiety for that purpose (having a formula  $L_n-N_y$ ), specifically, DNA sequencing primers containing six successive 6-histaminylpurine residues added on to the 5'-end of the DNA was synthesized. The 6-histaminylpurine moiety was introduced through the convertible nucleotide approach by analogy to reported procedures (Ferentz, A.E.; Verdine, G.L., *J. Am. Chem. Soc.* 1991, 113, 4000-4002; Ferentz, A.E.; Verdine, G.L. In *Nucleic Acids and Molecular Biology*; Eckstein, F.,  
25 Lilley, D.M.J. Eds.; Springer-Verlag: Berlin, 1994; Vol. 8, pp. 14-40. Briefly, resin-bound oligonucleotides containing O<sup>6</sup>-phenyl-2'-deoxyinosine ( $\phi$ dl) in place of the dH residue were deprotected from the resin by mild ammonia treatment (conc  $NH_4OH$ , nt, 4b) lyophilized to dryness, then treated with 5 M aqueous histamine (55°C, 14 h) to convert the  $\phi$ dl residues to dH.  
30 The crude oligonucleotides were purified by denaturing polyacrylamide gel electrophoresis. An additional dG residue was added at the 5'-end to ensure efficient end-labeling using polynucleotide kinase.

For the present IMAC-based strategy to be of significant practical value, it must be capable of resolving PCR-amplified duplex DNA into its two component strands. To test this application directly, we used one H<sub>6</sub>-tagged primer plus one unmodified primer to amplify a 183 base-pair segment of the plasmid pUC18-mARRE2, thereby to furnish a duplex product with an H<sub>6</sub>-tag on only one strand. The DNA template for PCR amplification, pUC18-mARRE2, was derived from the commercial cloning vector pUC18 by inserting a segment of the murine interleukin-2 enhancer into the *Bam*H I site (Chen, L.; Jain, J.; Oakley, M.G.; Glover, J.N.M.; Dervan, P.B.; Hogan, P.G.; Rao, A.; Verdine, G.L. *Curr. Biol.* 1995, 5, 882-889). pUC18 and close relatives are more widely used in bacterial cloning than each of the unbound and bound fractions was added 900 µl absolute ethanol (stored at 20°C), then the tubes were vortexed briefly and chilled for 30 min on dry powdered CO<sub>2</sub>. The tubes were microcentrifuged for 30 min at 16,000 x g. The supernatant was removed and the pellet washed with 200 µl 80% aqueous EtOH (-20°C). Following removal of the ethanol solution, the tubes were dried by centrifugal lyophilization (SpeedVac, Savant). To each dry tube was added 50 µl TE buffer. The DNA concentration was determined by UV spectrophotometry. The designation of "top" and "bottom" strands refers to the sequence as mapped in Figure 2. The "top" strand also corresponds to the coding strand of the lacZ' α peptide, part of which was encoded within the polylinker region of pUC18. That is, the PCR product generated using primers 1a + 2b will bear the H<sub>6</sub>-tag on the "top" strand only, whereas that generated using 2a + 1b will bear the H<sub>6</sub>-tag on the "bottom" strand only. The yield of PCR product formed in these reactions was no less than that observed in parallel reactions with only unmodified primers (data not shown), thus indicating that the H<sub>6</sub>-tag does not affect PCR amplification adversely.

Primers 1a/1b contain a sequence that is identical to a stretch (shaded) of the "top" strand of the plasmid pUC18-mARRE2; they are extended in the rightward direction (5'-3') during PCR. Primers 2a/2b contain a sequence that is identical to a stretch (shaded) of the "bottom" strand of pUC18-mARRE2; they are extended in the leftward direction. The shaded sequence in primers 1a and 2a denotes the H<sub>6</sub>-tag. *E* and *H* denote the *Eco*R I and *Hnd* III sites, respectively, of the pUC18 polylinker; a stretch of the murine IL-2 enhancer (mARRE2, batched) was inserted to the *Bam*H I site to generate pUC18-mARRE2. (c) Schematic illustration of the procedure for PCR amplification to produce duplex DNA containing a H<sub>6</sub>-tag on one strand, and resolution of the two constituent strands using IMAC.

### Example 2: Immobilization Of L<sub>6</sub>-N<sub>7</sub> At A Surface

The nucleotide including a moiety that can coordinate a metal ion was immobilized at a surface. Specifically, to assess the ability of the H<sub>6</sub>-tag to endow DNA with selective retentivity on a Ni<sup>2+</sup>-charged chelating resin, the H<sub>6</sub>-tagged oligonucleotides (2a/2b) and their unmodified counterparts (1b/2b) were 5'-end-labeled with <sup>32</sup>P, then passed in parallel through a Ni<sup>2+</sup>-nitrilotriacetic acid (NTA)-agarose resin. In particular, the PCR products were denatured in 6- M guanidinium-HCl, then incubated batch wise with Ni<sub>2</sub>-NTA-agarose.

### Example 3: Immobilization of a First Strand of First and Second Complementary Strands of DNA at a Surface with Selective Removal of the Second Strand, and Quantitative Determination of Bound Versus Unbound Strands

Following the procedure of Example 2, it was demonstrated that the H<sub>6</sub>-tag confers, upon an oligonucleotide, the ability to be selectively and reversibly retained on a surface, specifically Ni<sup>2+</sup>-NTA-agarose. In particular, it was demonstrated that the technique results in single-stranded oligonucleotide immobilized on a surface and free of hybridization to any complimentary strand that is also immobilized on the surface to the extent that the complimentary strand cannot be removed under conditions that cause denaturation of oligonucleotide strand from its complimentary strand.

Following removal of the supernatant, which contains unbound DNA, the resin was washed and the bound DNA eluted with 200 mM imidazole. Aliquots of the crude PCR product and the two DNA-containing fractions from the IMAC step were 5'-end labeled with <sup>32</sup>P and analyzed by denaturing polyacrylamide gel electrophoresis (PAGE). The use of PAGE as an assay for strand resolution was made possible by the slightly reduced mobility of H<sub>6</sub>-tagged DNA strands relative to their complimentary strands generated by PCT. The retarded mobility of the H<sub>6</sub>-tagged strand relative to the unmodified strand may arise from the partial positive charge of its 6 pendant imidazole moieties at pH 8 and a greater length, due to incomplete polymerization of the T<sub>6</sub>-stretch opposite H<sub>6</sub> during PCR. The identities of the strands were independently verified by PAGE analysis of PCR reactions that employed one <sup>32</sup>P-labeled primer and one nonradioactive primer. Although this slight difference in mobility provides a convenient means of assaying the strand resolution by IMAC, it is not sufficiently large to permit preparative strand resolution by gel electrophoresis and extraction.

Fig. 3 is a photocopy of the results of denaturing PAGE of DNA strand resolution using IMAC. Each panel of three lanes represents the results obtained using a pair of PCR primers,

one of which (1a or 2a) contains an H<sub>6</sub>-tag and the other of which (2b or 1b, respectively) is unmodified. C (lanes 1 and 4): controls showing the mixture of strands obtained directly by PCR, prior to IMAC resolution; U (lanes 2 and 5): unbound fractions from IMAC; B (lanes 3 and 6): bound fraction from IMAC, after elution with 200 mM imidazole.

5       The unbound fractions from IMAC in Fig. 3 contained primarily the faster-migrating species, which corresponds to the respective unmodified strands, whereas the imidazole-eluted bound fractions contained primarily the respective H<sub>6</sub>-tagged strands. Quantitative phosphoroimaging analysis from repeated runs of the strand resolution procedure revealed that the unmodified strand typically comprise >90% of the unbound DNA and the H<sub>6</sub>-tagged DNA  
10       comprise 95% of the bound fractions. Thus we conclude that IMAC cleanly resolves a uniquely H<sub>6</sub>-tagged PCR product into its two component strands. All but a trace amount of the bound radioactivity could be eluted from the resin upon washing with a 200mM aqueous imidazole.

#### Example 4: Template-Directed Polymerization Using Surface-Immobilized N<sub>6</sub>-N<sub>7</sub>

15       To assay the biological activity of single-stranded DNA generated through the PCR-IMAC sequence, we employed the resolved strands as templates in Sanger dideoxy sequencing runs. The experiment was carried out using oligonucleotide strands that had been synthesized so as to be attachable to a surface, in accordance with the invention, but were not attached to the surface during the experiment. Thus, the experiment proves the concept that the single-stranded  
20       oligonucleotide, immobilized at a surface in accordance with the invention, retains its biological activity.

Specifically, single-stranded DNA was immobilized at a surface of a column, as described above, and then the surface-immobilized DNA was flushed from the column, and a chelating agent was used to complex any remaining or free nickel ion in solution. Initially, the  
25       unmodified strands were found to be excellent sequencing templates, but the H<sub>6</sub>-tagged strands failed to support template-directed polymerization. Eventually, it was discovered that the H<sub>6</sub>-tagged DNA solutions contain adventitious Ni<sup>2+</sup> in amounts sufficient to cause profound inhibition of the DNA polymerase enzyme. This problem was overcome simply by adding 1,10-phenanthroline to the imidazole-containing eluate prior to precipitation with ethanol. Single-  
30       stranded templates prepared in this manner give uniformly high-quality DNA sequence data.

Those skilled in the art would readily appreciate that all parameters listed herein are meant to be exemplary and actual parameters will depend upon the specific application for which

the methods and arrangements of the present invention are being used. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and at that, within the scope of the appended claims and equivalence thereto, the invention may be practiced otherwise and as specifically described.


5

What is claimed is:

CLAIMS

1. A species having a formula  $L_n-N_y$ , where N represents a nucleotide, L represents a moiety that can coordinate a metal ion, n is at least one, and y is least one.

5 2. A species as in claim 1, wherein  $L_n$  has a generalized formula:



10 where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence.

3. A species as in claim 2, wherein Z is a hydrocarbon chain or a cyclic hydrocarbon  
15 group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon atoms.

4. A species as in either of claims 2 or 3, wherein Y, or Y and Z together, is a ligand that  
20 can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a metal affinity chromatography solid phase without complete coordination of the ion by the solid phase.

5. A species as in any of claims 2-4 wherein, wherein Y includes -N-, alcohols, thiols, carboxylates, imidazoles, phenanthroline, adenine, cytosine, thymine, histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, aspartate and hydroxamic acid, or a  
25 combination, that can address a vacant coordination site on a metal ion.

6. A species as in any preceding claim, wherein L represents a moiety that can coordinate a metal ion immobilized at a chromatography solid phase surface.

30 7. A species as in any preceding claim, wherein L is histaminylpurine and n is six.

8. A species as in any preceding claim, wherein  $N_y$  is DNA.

9. A species having a formula  $R-\text{Ch}-M-L_n-N_y$ , wherein R represents a chemical or



physical moiety, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent, N represents a nucleotide, L represents a moiety that can coordinate a metal ion, and n and y each is at least one.

5           10. A species as in claim 9, wherein R is a gold sol, a label such as a fluorescent label, a biological molecule of interest such as a binding partner for interaction with another species, a chromatography solid phase, or a linking or linkable moiety that can effect coupling of the species to any desired surface or species.

10           11. A species as in either of claims 9 or 10, wherein R is a species that promotes formation of a self-assembled monolayer of a plurality of similar species.

            12. A species as in any of claims 9-11, wherein Ch and M are together selected such that the dissociation constant of the combination in aqueous solution is better than 10 nM at  
15   physiological pH.

            13. A species as in any of claims 9-12, wherein Ch is nitrilotriacetic acid, 2,2'-bis (salicylidencamino)-6, 6'-demethyldiphenyl, or 1,8-bis (a-pyridyl)-3, 6-dithiaoctane.

20           14. A species as in any of claims 9-13, wherein Ch is a quadridentate chelating agent.

            15. A species as in claim 14, wherein Ch is nitrilotriacetic acid.

            16. A species as in any of claims 9-15, wherein Ch and M are together selected such that  
25   the chelating agent coordinates all but at least two of the metal coordination sites.

            17. A species as in any of claims 9-16, wherein Ch is a tetradentate chelating agent, and M has a coordination number of six.

30           18. A species as in any of claims 9-17, wherein M is Ni<sup>2+</sup>.


            19. A method comprising:

providing first and second complementary strands of oligonucleotide;  
 contacting a surface of a solid phase with the first and second strands; and  
 allowing the first strand to be immobilized at the surface while allowing the second  
 strand to be carried away from the surface without immobilization at the surface wherein the first  
 5 strand is immobilized at the surface via a linkage able to withstand conditions harsher than 2  
 molar urea.

20. A method as in claim 19, wherein the providing step comprises providing first and  
 second complementary strands of DNA in a fluid medium, and the contacting step comprises  
 10 passing the fluid medium across a surface of a solid phase.

21. A method as in either of claims 20-21, wherein the providing step involves providing  
 first and second complementary strands of oligonucleotide, the first strand represented by  $N_y$   
 where N is a nucleotide and the oligonucleotide is part of a species having a general formula  $L_n$ -  
 15  $N_y$ , where L represents a moiety that can coordinate a metal ion, n is at least one, and y is least  
 two.

22. A method as in claim 21, wherein  $L_n$  has a generalized formula:



where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion. Z and  
 25 Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence.

23. A method as in claim 22, wherein Z is a hydrocarbon chain or a cyclic hydrocarbon  
 group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon  
 atoms.

30

24. A method as in either of claims 22 or 23, wherein Y, or Y and Z together, is a ligand  
 that can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a  
 metal affinity chromatography solid phase without complete coordination of the ion by the solid  
 phase.

25. A method as in any of claims 22-24 wherein, wherein Y includes -N-, alcohols, thiols, carboxylates, imidazoles, phenanthroline, adenine, cytosine, thymine, histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, aspartate and hydroxamic acid, or a combination, that can address a vacant coordination site on a metal ion.

5

26. A method as in any of claims 21-25, wherein L represents a moiety that can coordinate a metal ion immobilized at a chromatography solid phase surface.

27. A method as in any of claims 21-26, wherein L is histaminy purine and n is six.

10

28. A method as in any of claims 21-27, wherein  $N_y$  is DNA.

15

29. A method as in either of claims 19 or 20, the following step involving allowing the first strand to be immobilized at the surface via a linkage  $R-Ch-M-L_n-N_y$ , wherein R represents the surface, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent,  $N_y$  represents the first strand, L represents a moiety that can coordinate a metal ion, n is at least one, and y is at least two.

20

30. A method as in claim 29, wherein R is a surface of gold sol or a surface of a chromatography solid phase.

31. A method as in claim 29, wherein R is a surface of a chromatography solid phase.

25

32. A method as in any of claims 29-31, wherein Ch and M are together selected such that the dissociation constant of the combination in aqueous solution is better than 10 nM at physiological pH.

30

33. A method as in any of claims 29-32, wherein Ch is nitrilotriacetic acid, 2,2'-bis (salicylidencarboxamido)-6, 6'-dimethyldiphenyl, or 1,8-bis (4-pyridyl)-3, 6-dithiaoctane.

34. A method as in any of claims 29-33, wherein Ch is a quadridentate chelating agent.

35. A method as in claim 34, wherein Ch is nitrilotriacetic acid.


36. A method as in any of claims 29-35, wherein Ch and M are together selected such that the chelating agent coordinates all but at least two of the metal coordination sites.

37. A method as in any of claims 29-36, wherein Ch is a tetradentate chelating agent, and M has a coordination number of six.

38. A method as in any of claims 29-37, wherein M is  $Ni^{2+}$ .

39. A species comprising a single-stranded oligonucleotide immobilized on a surface and free of hybridization to any complimentary strand that is also immobilized on the surface to the extent that the complimentary strand cannot be removed under conditions that cause denaturation of oligonucleotide strand from its complimentary strand, the single-stranded oligonucleotide being immobilized via linkage able to withstand conditions harsher than 2 molar urea.

40. A species as in claim 39, wherein the single-stranded oligonucleotide is immobilized via incorporation into a species having a formula  $L_n-N_y$ , where  $N_y$  represents the oligonucleotide, L represents a moiety that can coordinate a metal ion, n is at least one, and y is at least one,  $L_n$  has a generalized formula:




where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence.


41. A species as in claim 40, wherein L is histaminylpurine and n is six.

42. A species as in any of claims 39-41, wherein the single-stranded oligonucleotide is single-stranded DNA.

43. A species as in any of claims 39-42, wherein the single-stranded oligonucleotide is part of a species having a formula  $R-Ch-M-L_n-N_y$ , wherein R represents a chemical or physical moiety, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent,  $N_y$  represents the single-stranded oligonucleotide, L  
5 represents a moiety can coordinate a metal ion, and n is at least 2, and y is at least one.

44. A species as in claim 43, wherein R is a chromatography solid phase.

Fig. 1

Fig. 2




FIG. 3



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/11496

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07H21/00 C07H1/08 C07H19/04 C12Q1/68 G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 497 585 A (L.D.ANDERSON ET AL.) 5 August 1992	1-6,8,9
Y	see claims 1,3 see page 4, line 48 ---	1-44
X	US 5 453 356 A (A.J.BARD ET AL) 26 September 1995	1,8
Y	see claims 1,16,18-23,30 ---	1-44
X	WO 90 00622 A (WALLACOF; PHARMACIA AB) 25 January 1990 see the whole document ---	1-3,5,8
X	EP 0 285 057 A (ENZO BIOCHEM INC.) 5 October 1988 see the whole document ---	1-3,5,8
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

2 March 1998

Date of mailing of the international search report

11/03/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 97/11496

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 14841 A (BAXTER DIAGNOSTICS INC.) 3 September 1992 see the whole document ---	1-3,5,8
X	US 5 256 535 A (J.YLIKOSKI ET AL.) 26 October 1993 see column 19 - column 20; claims 1-9 ---	1-3,8
X	US 4 952 685 A (J.G.STAVRIANOPOULOS ) 28 August 1990 see abstract; table 1 ---	1,5
X	US 5 175 269 A (J.G.STAVRIANOPOULOS) 29 December 1992 see the whole document, but especially columns 12 and 32, example 6, and claims 1-6 ---	1,5
X	WO 96 02274 A (SCHERING AG ;NEXSTAR PHARMACEUTICALS INC (US)) 1 February 1996 see the whole document ---	1,8
X	US 5 238 808 A (BARD ALLEN J ET AL) 24 August 1993 see claims 1-11 ---	1,8
X	EP 0 340 675 A (PERKIN ELMER CORP) 8 November 1989 see claims 1-21 ---	1,8
X	WO 96 07668 A (CIBA GEIGY AG ;HAENER ROBERT (CH); HALL JONATHAN (CH); HUESKEN DIE) 14 March 1996 see abstract ---	1
X	EP 0 212 951 A (INTEGRATED GENETICS INC) 4 March 1987 see claims 5-12 ---	1
Y	GB 2 284 208 A (PNA DIAGNOSTICS AS) 31 May 1995 see the whole document, but especially page 7, line 20 to page 9, line 30 ---	1-44
Y	US 5 250 188 A (BRUENING RONALD L ET AL) 5 October 1993 see the whole document ---	1-44
Y	PORATH J: "IMAC-IMMOBILIZED METAL ION AFFINITY BASED CHROMATOGRAPHY" TRAC, TRENDS IN ANALYTICAL CHEMISTRY, AMSTERDAM, NL, vol. 7, no. 7, August 1988, pages 254-259, XP000001799 see the whole document ---	1-44
	2 -/--	

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 97/11496

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	C.MIN ET AL.: "Template Directed Interference of Footprinting of Protein-Adenine Contacts" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 26, 3 July 1996, US, pages 6116-6120, XP002057407 cited in the application see the whole document ---	1
A	US 5 294 369 A (SHIGEKAWA BRIAN L ET AL) 15 March 1994 see claims 1-15 ---	10
A	EP 0 519 250 A (MILES INC.) 23 December 1992 see abstract ---	10
P,X	C.MIN ET AL.: "Immobilized Metal Affinity Chromatography of DNA" NUCLEIC ACIDS RESEARCH., vol. 24, no. 19, 1 October 1996, OXFORD GB, pages 3806-10, XP002057408 cited in the application see the whole document ---	1-44
P,X	US 5 620 850 A (C.C.BAMDAD ET AL.) 15 April 1997 cited in the application see the whole document -----	1-44

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 497585 A	05-08-92	AU 652021 B	11-08-94
		AU 1054592 A	06-08-92
		AU 1365292 A	07-09-92
		CA 2060235 A	31-07-92
		JP 6157600 A	03-06-94
		NZ 241444 A	27-02-96
		WO 9213965 A	20-08-92
		US 5439829 A	08-08-95
		ZA 9200617 A	29-07-93
US 5453356 A	26-09-95	AU 5020085 A	15-05-86
		DE 3587793 D	11-05-94
		DE 3587793 T	18-08-94
		EP 0199804 A	05-11-86
		EP 0580979 A	02-02-94
		JP 9110890 A	28-04-97
		JP 7173185 A	11-07-95
		JP 6065271 A	08-03-94
		JP 8026054 B	13-03-96
		JP 62500663 T	19-03-87
		WO 8602734 A	09-05-86
		US 5714089 A	03-02-98
		US 5221605 A	22-06-93
		US 5238808 A	24-08-93
		US 5310687 A	10-05-94
WO 9000622 A	25-01-90	EP 0378652 A	25-07-90
		JP 3500248 T	24-01-91
EP 285057 A	05-10-88	AT 119164 T	15-03-95
		AU 585199 B	15-06-89
		AU 1617983 A	05-01-84
		AU 4149389 A	04-01-90
		CA 1223831 A	07-07-87
		DE 3382626 A	12-11-92
		DE 3382782 D	06-04-95
		DE 3382782 T	19-10-95
		DK 130684 A	29-02-84
		DK 130784 A	29-02-84
		DK 291183 A	24-12-83

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 285057 A		EP 0097373 A	04-01-84
		EP 0285058 A	05-10-88
		EP 0286898 A	19-10-88
		EP 0285950 A	12-10-88
		EP 0302175 A	08-02-89
		EP 0618228 A	05-10-94
		JP 2625095 B	25-06-97
		JP 59062600 A	10-04-84
		JP 6234787 A	23-08-94
		US 5241060 A	31-08-93
		US 5260433 A	09-11-93
-----			
WO 9214841 A	03-09-92	AT 156522 T	15-08-97
		AU 653012 B	15-09-94
		AU 1450792 A	15-09-92
		CA 2079448 A	15-08-92
		DE 69221404 D	11-09-97
		DE 69221404 T	05-02-98
		EP 0525181 A	03-02-93
		JP 5505201 T	05-08-93
		JP 6057717 B	03-08-94
-----			
US 5256535 A	26-10-93	SE 454781 B	30-05-88
		DE 3784058 A	18-03-93
		EP 0288513 A	02-11-88
		JP 1501681 T	15-06-89
		SE 8604436 A	18-04-88
		WO 8802784 A	21-04-88
-----			
US 4952685 A	28-08-90	US 4707440 A	17-11-87
		US 5002885 A	26-03-91
		US 5013831 A	07-05-91
		US 5175269 A	29-12-92
		AU 581577 B	23-02-89
		AU 3821285 A	29-08-85
		CA 1314503 A	16-03-93
		DK 39885 A	31-07-85
		EP 0154788 A	18-09-85
		EP 0810435 A	03-12-97
		JP 2110469 C	21-11-96

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4952685 A		JP 8000800 B	10-01-96
		JP 60197645 A	07-10-85
		US 4843122 A	27-06-89
		US 4849505 A	18-07-89
		US 4849208 A	18-07-89
		US 4943523 A	24-07-90
<hr/>			
US 5175269 A	29-12-92	US 4952685 A	28-08-90
		US 5013831 A	07-05-91
		US 4707440 A	17-11-87
		US 5002885 A	26-03-91
		AU 581577 B	23-02-89
		AU 3821285 A	29-08-85
		CA 1314503 A	16-03-93
		DK 39885 A	31-07-85
		EP 0154788 A	18-09-85
		EP 0810435 A	03-12-97
		JP 2110469 C	21-11-96
		JP 8000800 B	10-01-96
		JP 60197645 A	07-10-85
		US 4843122 A	27-06-89
		US 4849505 A	18-07-89
		US 4849208 A	18-07-89
		US 4943523 A	24-07-90
<hr/>			
WO 9602274 A	01-02-96	DE 4424922 A	18-01-96
		DE 4445078 A	13-06-96
		AU 2979195 A	16-02-96
		EP 0777498 A	11-06-97
		HU 76329 A	28-08-97
		NO 970141 A	14-03-97
		PL 318147 A	12-05-97
		SK 2897 A	10-09-97
		ZA 9505895 A	19-02-96
<hr/>			
US 5238808 A	24-08-93	AU 5020085 A	15-05-86
		DE 3587793 D	11-05-94
		DE 3587793 T	18-08-94
		EP 0199804 A	05-11-86
		EP 0580979 A	02-02-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5238808 A		JP 9110890 A	28-04-97
		JP 7173185 A	11-07-95
		JP 6065271 A	08-03-94
		JP 8026054 B	13-03-96
		JP 62500663 T	19-03-87
		WO 8602734 A	09-05-86
		US 5714089 A	03-02-98
		US 5310687 A	10-05-94
		US 5453356 A	26-09-95
		US 5221605 A	22-06-93
EP 0340675 A	08-11-89	US 4962045 A	09-10-90
		CA 1330030 A	07-06-94
		DE 68923035 D	20-07-95
		DE 68923035 T	19-10-95
		JP 2017445 A	22-01-90
WO 9607668 A	14-03-96	AU 3474495 A	27-03-96
		CA 2197788 A	14-03-96
		EP 0778844 A	18-06-97
		FI 970740 A	21-02-97
		NO 970886 A	25-04-97
EP 0212951 A	04-03-87	DE 3689019 D	21-10-93
		DE 3689019 T	05-05-94
		JP 2509574 B	19-06-96
		JP 62039598 A	20-02-87
		US 5155216 A	13-10-92
GB 2284208 A	31-05-95	AU 684118 B	04-12-97
		AU 1107595 A	13-06-95
		CA 2176745 A	01-06-95
		WO 9514708 A	01-06-95
		EP 0730602 A	11-09-96
		JP 9504050 T	22-04-97
		ZA 9409317 A	24-05-96
US 5250188 A	05-10-93	NONE	
US 5294369 A	15-03-94	AT 142341 T	15-09-96

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5294369 A		CA 2056843 A DE 69121849 D DE 69121849 T EP 0489465 A ES 2095291 T IE 75725 B JP 6116602 A US 5384073 A	06-06-92 10-10-96 06-02-97 10-06-92 16-02-97 24-09-97 26-04-94 24-01-95
EP 519250 A	23-12-92	CA 2070572 A JP 5188013 A	11-12-92 27-07-93
US 5620850 A	15-04-97	NONE	



CORRECTED  
VERSION\*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C07H 21/00, 1/08, 19/04, C12Q 1/68, G01N 33/543		A3	(11) International Publication Number: <b>WO 98/00435</b> (43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/US97/11496 (22) International Filing Date: 30 June 1997 (30.06.97)  (30) Priority Data: 60/021,195 3 July 1996 (03.07.96) US  (71) Applicant (for all designated States except US): PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; University Place, 124 Mount Auburn Street, Cambridge, MA 02138-5701 (US).  (72) Inventors; and (75) Inventors/Applicants (for US only): VERDINE, Gregory, L. [US/US]; 91 Outlook Drive, Lexington, MA 02173 (US). MIN, Changhee [KR/KR]; Doongji Apartment 109-1404, Doonsan Dong, Suh Ku, Daejeon 302-173 (KR).  (74) Agent: OYER, Timothy, J.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).			(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  (88) Date of publication of the international search report: 7 May 1998 (07.05.98)
(54) Title: OLIGONUCLEOTIDE LINKER AND TECHNIQUES INVOLVING IMMOBILIZED AND LINKED OLIGONUCLEOTIDES			
(57) Abstract  A technique is provided for linking an oligonucleotide, such as a single strand of DNA, to another moiety or solid phase. An oligonucleotide is provided with a linking functionality that can be defined by six neighboring histaminyal purines, which can be coordinated to a metal ion that also is coordinated by a chelating linked to a solid phase or other moiety. The invention finds particular use in resolution of one strand of DNA from its complement by providing the first strand with the linking functionality and passing the DNA across a metal affinity chromatography solid phase.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## **OLIGONUCLEOTIDE LINKER AND TECHNIQUES INVOLVING IMMOBILIZED AND LINKED OLIGONUCLEOTIDES**

### **Field of the Invention**

5           The present invention relates generally to the production of single-stranded DNA molecules, and more particularly to the production of single-stranded DNA using immobilized metal affinity chromatography.

### **Background of the Invention**

10           Many of the most widely employed operations in molecular biology hinge upon the use of single-stranded DNA as a probe or template. Whereas single strands of DNA containing up to approximately 100 residues can readily be produced by solid-phase synthesis, longer oligodeoxynucleotides typically must be generated through enzymatic methods such as the polymerase chain reaction (PCR). Because biochemical procedures for the synthesis of mixed-  
15           sequence DNA yield double-stranded products, there exists a need for a method by which to resolve a desired strand from its complement. Such resolution is rendered difficult by the similarities in macroscopic physical properties such as size and charge of two complementary strands, and by the requirement that resolution be carried out in the presence of strong denaturants such as urea or guanidinium hydrochloride.

20           Techniques exist for attaching a single biotin onto an oligonucleotide, then using a solid matrix at which is immobilized avidin or streptavidin, to immobilize the oligonucleotide. A problem with this approach is that the binding that is required for the technique to be effective depends upon proteins being properly folded. Therefore, the technique cannot be used under strong denaturing conditions. Also, if the technique is to be used to surface-immobilize a single  
25           DNA strand for surface plasmon resonance studies, the avidin/biotin combination adds enough mass to the surface that the technique, when used to detect binding of a single strand of DNA to the immobilized strand, can lack precision.

          It is, therefore, a object of the present invention to provide improved techniques for linking an oligonucleotide such as DNA, or a single strand of DNA, to another moiety or a  
30           surface, and to resolve a desired strand of DNA from its complement.

### **Summary of the Invention**

          The present invention provides a nucleotide coupled to a linking moiety that can

coordinate a metal ion, namely, a species having a formula  $L_n-N_y$ , where N represents the nucleotide and L represents the moiety which can coordinate a metal ion. n is at least 1, and y is at least 1. According to one embodiment  $N_y$  is DNA, and L can be histaminylpurine where n is approximately 6.

5           According to another aspect, the invention provides a species having a formula  $R-Ch-M-L_n-N_y$ . According to this aspect, R represents a chemical moiety that can be linked to a surface, or linked to a chemical or biological species. Ch represents a chelating agent that can coordinate a metal ion. M represents a metal ion coordinated by the chelating agent, N represents a nucleotide. L represents a moiety that can coordinate a metal ion, and n and y each is at least 1.

10           The chelating agent is, according to one embodiment, a quadridentate chelating agent, for example nitrilotriacetic acid.

          The invention also provides a single stranded oligonucleotide immobilized on a surface and free of hybridization to any complementary strand that is also immobilized on the surface to the extent that the complementary strand cannot be removed under conditions that cause  
15   denaturation of oligonucleotide strand from its complementary strand. The single-stranded immobilized oligonucleotide also will withstand conditions, while remaining immobilized, harsher than 2 molar urea. The strand can be a strand of DNA.

          According to another aspect the invention provides a method. The method involves providing first and second complementary strands of oligonucleotide, contacting a surface of a  
20   solid phase with the first and second strands, and allowing the first strand to be immobilized at the surface. The second strand is allowed to be carried away from the surface without immobilization at the surface. According to one embodiment, this aspect involves providing first and second complementary strands of DNA in a fluid medium, passing the fluid medium across a surface of a solid phase, and allowing the first strand to be immobilized at the surface while the  
25   second strand is allowed to be carried by the fluid medium away from the surface without immobilization.

          The various aspects of the invention can be combined in a variety of ways. For example, the single stranded oligonucleotide immobilized on a surface and free of hybridization to any complementary strand that is also immobilized on the surface to the extent that the  
30   complementary strand cannot be removed under conditions that cause denaturation, can be immobilized via linkages such as  $L_n-N_y$  or  $R-Ch-M-L_n-N_y$ , above. Additionally, the methods can be practiced using any of the species that can facilitate immobilization of an oligonucleotide.

Other advantages, novel features, and objects of the invention will become apparent from the following detailed description of the invention when considered in conjunction with the accompanying drawings.

### Brief Description of the Drawings

Fig. 1 is a schematic representation of double-stranded DNA immobilized, via an attached linking moiety coordinated to a metal ion, to a solid phase surface;

Fig. 2 illustrates, schematically, primers and double-stranded PCR template used in one set of examples; and

Fig. 3 is a photocopy of a denaturing polyacrylamide gel electrophoresis analysis of DNA strand resolution using a technique of the present invention.

### Detailed Description of the Invention

Min, C., Cushing, T. Verdine, G., "Template-Directed Interference Footprinting of Protein-Adenine Contacts," *J. Am. Chem. Soc.* 1996, 118, 6116-6120; and Min, C. Verdine, G., "Immobilized Metal Affinity Chromatography of DNA," *Nucleic Acids Res.* 1996, 24, 3806-3810. both are incorporated herein by reference.

The present invention provides a linking functionality for attachment of an oligonucleotide to another moiety or to a surface of a solid phase, where solid phase is defined as any material insoluble in a medium used in conjunction with a procedure involving the oligonucleotide. The technique can be used, for example, to link an oligonucleotide to a solid phase surface such as a chromatography solid phase, or to a surface of a biosensor element such as a surface plasmon resonance (SPR) chip (for a discussion of SPR see, for example, Sternberg, et al., "Quantitative Determination of Surface Concentration of Protein with Surface Plasmon Resonance Using Radiolabeled Proteins", *Journal of Colloid and Interface Science*, 43:2 513-526, 1991, and references therein). The technique also can be used, for example, to link an oligonucleotide to a surface of a bead or plate used in a bioassay, to a label such as a fluorescent label, or another molecule or solid entity.

The invention involves providing a species having the generalized formula  $L_n-N_y$ , where  $N_y$  represents a natural or synthetic, single or multiple-strand oligonucleotide typified in DNA or a strand of DNA, and  $L_n$  represents a linking functionality where  $L$  represents a ligating moiety that can coordinate a metal ion, and  $n$  is at least 1, preferably at least 2, and more preferably at


least 5. According to preferred embodiments, n is from 2 to 10, and most preferably is about 6. L is a molecule that can be chemically attached to an oligonucleotide via, for example, the ester bond of the oligonucleotide backbone, and  $L_n$  has a generalized formula I, below.



where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence. Those of ordinary skill in the art can select appropriately Y and Z to meet the requirement of compatibility with an oligonucleotide sequence. Z and Y can be a single moiety in that a single organic moiety can provide functionality compatible with an oligonucleotide sequence and also coordinate a metal ion. Typically, Z is a hydrocarbon chain or a cyclic hydrocarbon group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon atoms. As used herein, "hydrocarbon" is meant to include alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkaryl, aralkyl, and the like. Hetero groups can include -O-, -CONH-, -CONHCO-, -NH-, -CSNH-, -CO-, -CS-, -S-, -SO-,  $-(\text{OCH}_2\text{CH}_2)_n\text{R}$  (where  $n=1-10$ ),  $-(\text{CF}_2)_n-$  (where  $n=1-10$ ), olefins, and the like.

Y (or Y and Z together) is a ligand that can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a metal affinity chromatography solid phase without complete coordination of the ion by the solid phase (see, for example, Hochuli et al., "New Metal Chelate Adsorbent Selective for Proteins and Peptides Containing Neighboring Histidine Residues" *Journal of Chromatography*, 411 (1987) 177-184). Y can be as defined above for Z, and preferably includes groups such as -N-, alcohols, thiols, carboxylates (including carboxylic acid), and the like which can address a vacant coordination site on a metal ion. Cyclic and heterocyclic organic compounds including -N- such as imidazoles, phenanthroline, adenine, cytosine, and thymine are suitable. Additionally, amino acids satisfying these criteria, such as histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, and aspartate are suitable. Species such as hydroxamic acid also are suitable. In some cases, the above moieties can serve as Z, with a different one of the above or another moiety serving as Y and satisfying the criterion of coordination to a metal ion. For example, purine, thymine, adenine,

cytosine, or a combination could serve as Z, with another nucleic acid, amino acid, or nitrogen-containing cyclic, multi-cyclic, or heterocyclic compound serving as Y. Where, for example, purine, cytosine, or adenine are used as Z, the available -NH<sub>2</sub>- group can be used to couple Y defined by, for example, histamine. According to one preferred embodiment, 6-histaminyl purine defines Y, and Z is a cyclic ether (II, below).



(II)

Species L<sub>n</sub>-N<sub>y</sub> finds use in conjunction with a metal ion partially coordinated by a chelating agent that is linked, or can be linked, to a moiety or surface of interest. That is, the species finds use in a combination of the formula:



where R represents a chemical or physical moiety, Ch represents a chelating agent that can coordinate a metal ion, and M represents a metal ion coordinated by the chelating agent. R can be a particulate species such as gold sol, a label such as a fluorescent label, a biological molecule of interest such as a binding partner for interaction with another species, a chromatography solid phase, or a linking or linkable moiety that can effect coupling of species III to any desired surface or species. The particular species or surface to which species III is coupled is not important, but the invention lies in the ability to coordinate N<sub>y</sub> to R via L<sub>n</sub>.

Co-pending, commonly-owned U.S. Patent Application Serial No. 08/312,388, filed September 26, 1994, now U.S. Patent No. 5,620,850, and incorporated herein by reference,

describes a variety of combinations of Ch and M suitable for use in the invention. In particular, the metal ion is preferably selected from those that have at least four coordination sites, preferably six coordination sites. A non-limiting list of metal ions suitable includes  $\text{Co}^{3+}$ ,  $\text{Cr}^{3+}$ ,  $\text{Hg}^{2+}$ ,  $\text{Pd}^{2+}$ ,  $\text{Pt}^{2+}$ ,  $\text{Pd}^{4+}$ ,  $\text{Pt}^{4+}$ ,  $\text{Rh}^{3+}$ ,  $\text{Ir}^{3+}$ ,  $\text{Ru}^{3+}$ ,  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$ ,  $\text{Cu}^{2+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Cd}^{2+}$ ,  $\text{Pb}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Fe}^{3+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Au}^{3+}$ ,  $\text{Au}^+$ ,  $\text{Ag}^+$ ,  $\text{Cu}^+$ ,  $\text{MO}_2^{2+}$ ,  $\text{Tl}^{3+}$ ,  $\text{Tl}^+$ ,  $\text{Bi}^{3+}$ ,  $\text{CH}_3\text{Hg}^+$ ,  $\text{Al}^{3+}$ ,  $\text{Ga}^{3+}$ ,  $\text{Ce}^{3+}$ ,  $\text{UO}_2^{2+}$ , and  $\text{La}^{3+}$ .

The chelating agent is preferably selected from bidentate, tridentate, and quadridentate, chelating agents, and is selected in conjunction with the metal ion so that when the chelating agent coordinates the metal ion, at least two free coordination sites of the metal remain. The chelating agent and metal are selected so that the chelating agent can coordinate the metal ion with a degree of stability great enough that the metal ion will remain immobilized at the surface by the chelating agent.

Additionally, the chelating agent is selected as one that has a chelating moiety and a non-chelating linker moiety, such that it can be covalently linked via its linker moiety to the moiety R while leaving the chelating moiety undisturbed by the covalent linkage and free to coordinate a metal ion. Alternatively, the chelating agent can be selected as one that can be modified via routine organic synthesis to include a non-chelating linker moiety, if such synthesis leaves undisturbed the chelating moiety. One of ordinary skill in the art will appreciate that the non-chelating linker moiety should provide functionality suitable for chemical linkage such as, for example, an amine, alcohol, carbamate, carboxylic acid, thiol, aldehyde, olefin, etc., for formation of an ester linkage, formation of an amide linkage, thiol displacement and thiol ether formation, and the like.

With the above considerations in mind, suitable chelating agents and corresponding metal ions can be selected by those of ordinary skill in the art. In accordance with such selection reference can be made to "Chelating Agents and Metal Chelates", Dwyer, F. P.; Mellor, D. P., Academic Press, and "Critical Stability Constants", Martell, A. E.; Smith, R. M., Plenum Press, New York. These works describe a variety of chelating agents, and discuss the stability of coordination between chelating agents and metal ions. Preferably, a chelating agent and metal ion is selected such that the dissociation constant of the combination in aqueous solution is better than 10 nM at physiological pH, that is, such that at least one half of the metal ions are coordinated by chelating agent at a concentration of 10 nM.

A non-limiting exemplary list of suitable chelating agents includes nitrilotriacetic acid, 2,2'-bis(salicylidencamino)-6,6'-demethyldiphenyl, and 1,8-bis(a-pyridyl)-3,6-dithiaoctane.



As an example of one, preferred arrangement using species III, reference is made to Fig. 1, in which a species 25 linked to a solid phase surface includes an oligonucleotide, in particular DNA 10 including a first strand 12 and a second, complementary strand 14 including a linking functionality ( $L_n$ ) 16 defined by 6 histaminyl purines, two of which (18 and 20, respectively) are coordinated to a metal ion 22. Metal ion 22 also is coordinated by chelating agent 24 (a nitrilotriacetic acid derivative, as illustrated) which coordinates four of the six coordination sites of the metal ion, leaving two free coordination sites addressable by linking functionality 16. Chelating agent 24 is attached, via linker 26 (a hydrocarbon chain, as illustrated), to a surface 28 of a solid phase 30. Linkage of chelating agent 24 to surface 28 via linker 26 can be accomplished by any means such as covalent attachment, or the like.

A single-stranded oligonucleotide also is usefully immobilized as shown in FIG. 1 in accordance with the invention. According to one embodiment, linker 26 is selected as one that promotes formation of a self-assembled monolayer of a plurality of linkers 26 at surface 28, and linker 26 terminates at its end opposite the chelating agent in a functionality that is attracted to surface 28 and thereby promotes formation of a self-assembled monolayer. Such an arrangement of a metal-coordinating chelating agent immobilized at a surface as part of a self-assembled monolayer is described in commonly-owned co-pending U.S. patent application serial number 08/312,388, now U.S. Patent No. 5,620,850, referenced above. Self-assembled monolayer-forming species also are described in U.S. Patent No. 5,512,131, issued April 30, 1996 to Kumar and Whitesides, incorporated herein by reference. Where a self-assembled monolayer containing a chelating agent 24 is provided for use with species  $L_n-N_y$  such as DNA 10 including linking functionality 16, it can be advantageous to form a self-assembled mixed monolayer (as defined in application serial number 08/312,388, and U.S. Patent No. 5,620,850 referenced above), that is, a heterogeneous self-assembled monolayer including an ordered assembly of at least another self-assembled monolayer-forming species other than species 25. A heterogeneous monolayer defined by less than about 50% of species 25 and greater than about 50% of another species such as one terminating in a moiety that does not interact with  $L_n$  or  $N_y$  can be formulated, as well as one with a ratio of less than about 30% species 25, or less than about 20% species 25, etc.

It is to be understood that coordination of linking functionality 16 to M may involve linkage via two neighboring ligating moieties L (H, for histaminyl purine, as illustrated in FIG. 1), or another arrangement. Additionally, linking functionality 16 may include neighboring ligating moieties L and/or ligating moieties L separated by one or more intermediate moieties

that do not have ligating capacity, so long as linking functionality 16 possesses the ability to coordinate free coordination sites at M.

Referring again to formula I, Y (and Y in combination with Z if Z has coordinating capacity) and n should be selected to provide the oligonucleotide with coordinating capacity sufficient to link the oligonucleotide to a metal ion to the extent that the oligonucleotide does not become detached from the metal ion during the course of a procedure involving the oligonucleotide coordinated to the metal ion so as, for example, to immobilize the oligonucleotide at a solid phase. Coordination should not, however, be so strong that  $L_n$  will compete with coordination of the metal ion by the chelating agent to the extent that the metal ion is stripped from the chelating agent (thus, e.g., stripped from a solid phase, label, or other moiety). For example, in most cases ligands such as ethylenediamine tetra acetic acid would be unsuitable. Those of ordinary skill in the art, with reference to "Chelating Agents and Metal Chelates," Dwyer, F.P.; Mellor, D.P., Academic Press, and "Critical Stability Constants", Martell, A.E.; Smith, R.M., Plenum Press, New York, can select a suitable group Y (and optionally Z) and the number of repeating units n for a particular metal ion including a particular number of free coordination sites.

In some cases it can be advantageous to test a particular  $L_n$ /M-Ch system to determine whether coordination will be sufficiently stable for use in the present invention, but will not be so stable that the metal ion is stripped from the chelating agent. For example, it is within the realm of routine experimentation to one of ordinary skill in the art to prepare a very simple polynucleotide containing as few as two nucleotides or up to approximately 6 or 8 with an attached linking functionality  $L_n$ , i.e., 3'-NNNNN- $L_n$ , where N is any nucleotide or a variety of nucleotides. The test oligonucleotide then can be labeled radioactively at the 5' end by mixing with  $T_4$  polynucleotide kinase, then with  $\gamma^{32}\text{P}$ -ATP. Then the oligonucleotide can be mixed with beads of resin containing immobilized, coordinated metal ion, the beads rinsed, and determination can be made as to whether radioactivity is present at the beads. If radioactivity is present, then the selection of L (i.e. Y or Y and R together) and n is appropriate to provide coordination capacity sufficient to immobilize the oligonucleotide, but not to the extent that the metal ion is stripped from the chelating agent.

If radioactivity is not present at the beads, then determination of whether the L, n combination results in insufficient coordination or coordination to an excessive extent such that metal ion is stripped can be made by subjecting the beads, and/or the solution used to flush the

beads, to ultraviolet spectroscopy or ICP to determine the location of the metal ion. These simple screening techniques can be performed by one of ordinary skill in the art without the necessity of synthesizing an entire oligonucleotide such as a DNA fragment useful in a particular procedure.

5 In some cases one would want to be able to separate the linker-nucleotide from the metal ion, as in elution from a column, and in some cases one would want essentially irreversible binding. Accordingly, as a second test, beads can be flushed with an eluting fluid such as 200mM imidazole and determination made as to whether the radioactivity is still present at the beads.

10 The present invention also represents an improvement over immobilization of single-stranded oligonucleotide at a surface via biotin/avidin or biotin/streptavidin linkage. That linkage will withstand conditions only up to 2 molar urea, or less. The present invention involves immobilization that withstands conditions harsher than 2 molar urea.

The function and advantage of these and other embodiments of the present invention will  
15 be more fully understood from the examples below. The following examples are intended to illustrate the benefits of the present invention, but do not exemplify the full scope of the invention.

#### Example 1: Synthesis Of A Nucleotide Including A Moiety That Can Coordinate A Metal Ion

20 A nucleotide that can coordinate a metal ion due to incorporation of a moiety for that purpose (having a formula  $L_n-N_y$ ), specifically, DNA sequencing primers containing six successive 6-histaminylpurine residues added on to the 5'-end of the DNA was synthesized. The 6-histaminylpurine moiety was introduced through the convertible nucleotide approach by analogy to reported procedures (Ferentz, A.E.; Verdine, G.L., *J. Am. Chem. Soc.* 1991, 113, 4000-4002; Ferentz, A.E.; Verdine, G.L. In *Nucleic Acids and Molecular Biology*; Eckstein, F.,  
25 Lilley, D.M.J. Eds.; Springer-Verlag: Berlin, 1994; Vol. 8, pp. 14-40. Briefly, resin-bound oligonucleotides containing O<sup>6</sup>-phenyl-2'-deoxyinosine ( $\phi$ dl) in place of the dH residue were deprotected from the resin by mild ammonia treatment (conc  $NH_4OH$ , rt, 4h) lyophilized to dryness, then treated with 5 M aqueous histamine (55°C, 14 h) to convert the  $\phi$ dl residues to dH.  
30 The crude oligonucleotides were purified by denaturing polyacrylamide gel electrophoresis. An additional dG residue was added at the 5'-end to ensure efficient end-labeling using polynucleotide kinase.

For the present IMAC-based strategy to be of significant practical value, it must be capable of resolving PCR-amplified duplex DNA into its two component strands. To test this application directly, we used one H<sub>6</sub>-tagged primer plus one unmodified primer to amplify a 183 base-pair segment of the plasmid pUC18-mARRE2, thereby to furnish a duplex product with an H<sub>6</sub>-tag on only one strand. The DNA template for PCR amplification, pUC18-mARRE2, was derived from the commercial cloning vector pUC18 by inserting a segment of the murine interleukin-2 enhancer into the *Bam*HI site (Chen, L.; Jain, J.; Oakley, M.G.; Glover, J.N.M.; Dervan, P.B.; Hogan, P.G.; Rao, A.; Verdine, G.L. *Curr. Biol.* 1995, 5, 882-889). pUC18 and close relatives are more widely used in bacterial cloning than each of the unbound and bound fractions was added 900 µl absolute ethanol (stored at 20°C), then the tubes were vortexed briefly and chilled for 30 min on dry powdered CO<sub>2</sub>. The tubes were microcentrifuged for 30 min at 16,000 x g. The supernatant was removed and the pellet washed with 200 µl 80% aqueous EtOH (-20°C). Following removal of the ethanol solution, the tubes were dried by centrifugal lyophilization (SpeedVac, Savant). To each dry tube was added 50 µl TE buffer. The DNA concentration was determined by UV spectrophotometry. The designation of "top" and "bottom" strands refers to the sequence as mapped in Figure 2. The "top" strand also corresponds to the coding strand of the lacZ'α peptide, part of which was encoded within the polylinker region of pUC18. That is, the PCR product generated using primers 1a + 2b will bear the H<sub>6</sub>-tag on the "top" strand only, whereas that generated using 2a + 1b will bear the H<sub>6</sub>-tag on the "bottom" strand only. The yield of PCR product formed in these reactions was no less than that observed in parallel reactions with only unmodified primers (data not shown), thus indicating that the H<sub>6</sub>-tag does not affect PCR amplification adversely.

Primers 1a/1b contain a sequence that is identical to a stretch (shaded) of the "top" strand of the plasmid pUC18-mARRE2; they are extended in the rightward direction (5'-3') during PCR. Primers 2a/2b contain a sequence that is identical to a stretch (shaded) of the "bottom" strand of pUC18-mARRE2; they are extended in the leftward direction. The shaded sequence in primers 1a and 2a denotes the H<sub>6</sub>-tag. E and H denote the *Eco*R I and *Hind* III sites, respectively, of the pUC18 polylinker; a stretch of the murine IL-2 enhancer (mARRE2, batched) was inserted to the *Bam*HI site to generate pUC18-mARRE2. (c) Schematic illustration of the procedure for PCR amplification to produce duplex DNA containing a H<sub>6</sub>-tag on one strand, and resolution of the two constituent strands using IMAC.

### Example 2: Immobilization Of L<sub>6</sub>-N<sub>7</sub> At A Surface

The nucleotide including a moiety that can coordinate a metal ion was immobilized at a surface. Specifically, to assess the ability of the H<sub>6</sub>-tag to endow DNA with selective retentivity on a Ni<sup>2+</sup>-charged chelating resin, the H<sub>6</sub>-tagged oligonucleotides (2a/2b) and their unmodified counterparts (1b/2b) were 5'-end-labeled with <sup>32</sup>P, then passed in parallel through a Ni<sup>2+</sup>-nitrilotriacetic acid (NTA)-agarose resin. In particular, the PCR products were denatured in 6- M guanidinium·HCl, then incubated batch wise with Ni<sub>2+</sub>-NTA-agarose.

### Example 3: Immobilization of a First Strand of First and Second Complementary Strands of DNA at a Surface with Selective Removal of the Second Strand, and Quantitative Determination of Bound Versus Unbound Strands

Following the procedure of Example 2, it was demonstrated that the H<sub>6</sub>-tag confers, upon an oligonucleotide, the ability to be selectively and reversibly retained on a surface, specifically Ni<sup>2+</sup>-NTA-agarose. In particular, it was demonstrated that the technique results in single-stranded oligonucleotide immobilized on a surface and free of hybridization to any complementary strand that is also immobilized on the surface to the extent that the complementary strand cannot be removed under conditions that cause denaturation of oligonucleotide strand from its complementary strand.

Following removal of the supernatant, which contains unbound DNA, the resin was washed and the bound DNA eluted with 200 mM imidazole. Aliquots of the crude PCR product and the two DNA-containing fractions from the IMAC step were 5'-end labeled with <sup>32</sup>P and analyzed by denaturing polyacrylamide gel electrophoresis (PAGE). The use of PAGE as an assay for strand resolution was made possible by the slightly reduced mobility of H<sub>6</sub>-tagged DNA strands relative to their complementary strands generated by PCT. The retarded mobility of the H<sub>6</sub>-tagged strand relative to the unmodified strand may arise from the partial positive charge of its 6 pendant imidazole moieties at pH 8 and a greater length, due to incomplete polymerization of the T<sub>6</sub>-stretch opposite H<sub>6</sub> during PCR. The identities of the strands were independently verified by PAGE analysis of PCR reactions that employed one <sup>32</sup>P-labeled primer and one nonradioactive primer. Although this slight difference in mobility provides a convenient means of assaying the strand resolution by IMAC, it is not sufficiently large to permit preparative strand resolution by gel electrophoresis and extraction.

Fig. 3 is a photocopy of the results of denaturing PAGE of DNA strand resolution using IMAC. Each panel of three lanes represents the results obtained using a pair of PCR primers,

one of which (1a or 2a) contains an H<sub>6</sub>-tag and the other of which (2b or 1b, respectively) is unmodified. C (lanes 1 and 4): controls showing the mixture of strands obtained directly by PCR, prior to IMAC resolution; U (lanes 2 and 5): unbound fractions from IMAC; B (lanes 3 and 6): bound fraction from IMAC, after elution with 200 mM imidazole.

5           The unbound fractions from IMAC in Fig. 3 contained primarily the faster-migrating species, which corresponds to the respective unmodified strands, whereas the imidazole-eluted bound fractions contained primarily the respective H<sub>6</sub>-tagged strands. Quantitative phosphorimaging analysis from repeated runs of the strand resolution procedure revealed that the unmodified strand typically comprise >90% of the unbound DNA and the H<sub>6</sub>-tagged DNA  
10       comprise 95% of the bound fractions. Thus we conclude that IMAC cleanly resolves a uniquely H<sub>6</sub>-tagged PCR product into its two component strands. All but a trace amount of the bound radioactivity could be eluted from the resin upon washing with a 200mM aqueous imidazole.

#### Example 4: Template-Directed Polymerization Using Surface-Immobilized N<sub>n</sub>-N<sub>y</sub>

15           To assay the biological activity of single-stranded DNA generated through the PCR-IMAC sequence, we employed the resolved strands as templates in Sanger dideoxy sequencing runs. The experiment was carried out using oligonucleotide strands that had been synthesized so as to be attachable to a surface, in accordance with the invention, but were not attached to the surface during the experiment. Thus, the experiment proves the concept that the single-stranded  
20       oligonucleotide, immobilized at a surface in accordance with the invention, retains its biological activity.

          Specifically, single-stranded DNA was immobilized at a surface of a column, as described above, and then the surface-immobilized DNA was flushed from the column, and a chelating agent was used to complex any remaining or free nickel ion in solution. Initially, the  
25       unmodified strands were found to be excellent sequencing templates, but the H<sub>6</sub>-tagged strands failed to support template-directed polymerization. Eventually, it was discovered that the H<sub>6</sub>-tagged DNA solutions contain adventitious Ni<sup>2+</sup> in amounts sufficient to cause profound inhibition of the DNA polymerase enzyme. This problem was overcome simply by adding 1,10-phenanthroline to the imidazole-containing eluate prior to precipitation with ethanol. Single-  
30       stranded templates prepared in this manner give uniformly high-quality DNA sequence data.

          Those skilled in the art would readily appreciate that all parameters listed herein are meant to be exemplary and actual parameters will depend upon the specific application for which

the methods and arrangements of the present invention are being used. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and at that, within the scope of the appended claims and equivalence thereto, the invention may be practiced otherwise and as specifically described.


5

What is claimed is:

CLAIMS

1. A species having a formula  $L_n-N_y$ , where N represents a nucleotide, L represents a moiety that can coordinate a metal ion, n is at least one, and y is least one.

5 2. A species as in claim 1, wherein  $L_n$  has a generalized formula:



10 where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence.

3. A species as in claim 2, wherein Z is a hydrocarbon chain or a cyclic hydrocarbon  
15 group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon atoms.

4. A species as in either of claims 2 or 3, wherein Y, or Y and Z together, is a ligand that  
20 can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a metal affinity chromatography solid phase without complete coordination of the ion by the solid phase.

5. A species as in any of claims 2-4 wherein, wherein Y includes -N-, alcohols, thiols, carboxylates, imidazoles, phenanthroline, adenine, cytosine, thymine, histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, aspartate and hydroxamic acid, or a  
25 combination, that can address a vacant coordination site on a metal ion.

6. A species as in any preceding claim, wherein L represents a moiety that can coordinate a metal ion immobilized at a chromatography solid phase surface.

30 7. A species as in any preceding claim, wherein L is histaminylpurine and n is six.

8. A species as in any preceding claim, wherein  $N_y$  is DNA.

9. A species having a formula  $R-\text{Ch}-M-L_n-N_y$ , wherein R represents a chemical or



physical moiety, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent, N represents a nucleotide, L represents a moiety can coordinate a metal ion, and n and y each is at least one.

5           10. A species as in claim 9, wherein R is a gold sol, a label such as a fluorescent label, a biological molecule of interest such as a binding partner for interaction with another species, a chromatography solid phase, or a linking or linkable moiety that can effect coupling of the species to any desired surface or species.

10           11. A species as in either of claims 9 or 10, wherein R is a species that promotes formation of a self-assembled monolayer of a plurality of similar species.

            12. A species as in any of claims 9-11, wherein Ch and M are together selected such that the dissociation constant of the combination in aqueous solution is better than 10 nM at  
15   physiological pH.

            13. A species as in any of claims 9-12, wherein Ch is nitrilotriacetic acid, 2,2'-bis (salicylidencamino)-6, 6'-demethyldiphenyl, or 1,8-bis (a-pyridyl)-3, 6-dithiaoctane.

20           14. A species as in any of claims 9-13, wherein Ch is a quadradentate chelating agent.

            15. A species as in claim 14, wherein Ch is nitrilotriacetic acid.

            16. A species as in any of claims 9-15, wherein Ch and M are together selected such that  
25   the chelating agent coordinates all but at least two of the metal coordination sites.

            17. A species as in any of claims 9-16, wherein Ch is a tetradentate chelating agent, and M has a coordination number of six.

30           18. A species as in any of claims 9-17, wherein M is Ni<sup>2+</sup>.

            19. A method comprising:

providing first and second complementary strands of oligonucleotide;  
 contacting a surface of a solid phase with the first and second strands; and  
 allowing the first strand to be immobilized at the surface while allowing the second  
 strand to be carried away from the surface without immobilization at the surface wherein the first  
 5 strand is immobilized at the surface via a linkage able to withstand conditions harsher than 2  
 molar urea.

20. A method as in claim 19, wherein the providing step comprises providing first and  
 second complementary strands of DNA in a fluid medium, and the contacting step comprises  
 10 passing the fluid medium across a surface of a solid phase.

21. A method as in either of claims 20-21, wherein the providing step involves providing  
 first and second complementary strands of oligonucleotide, the first strand represented by  $N_y$ ,  
 where N is a nucleotide and the oligonucleotide is part of a species having a general formula  $L_n$ -  
 15  $N_y$ , where L represents a moiety that can coordinate a metal ion, n is at least one, and y is least  
 two.

22. A method as in claim 21, wherein  $L_n$  has a generalized formula:



where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and  
 25 Y together allowing incorporation of  $L_n$  into or on an oligonucleotide sequence.

23. A method as in claim 22, wherein Z is a hydrocarbon chain or a cyclic hydrocarbon  
 group, optionally interrupted by hetero groups, of a length of from about 1 to about 10 carbon  
 atoms.  
 30

24. A method as in either of claims 22 or 23, wherein Y, or Y and Z together, is a ligand  
 that can coordinate free coordination sites on a metal ion, such as a metal ion immobilized on a  
 metal affinity chromatography solid phase without complete coordination of the ion by the solid  
 phase.

25. A method as in any of claims 22-24 wherein, wherein Y includes -N-, alcohols, thiols, carboxylates, imidazoles, phenanthroline, adenine, cytosine, thymine, histidine, lysine, cysteine, methionine, asparagine, tyrosine, glutamine, glutamate, aspartate and hydroxamic acid, or a combination, that can address a vacant coordination site on a metal ion.

5

26. A method as in any of claims 21-25, wherein L represents a moiety that can coordinate a metal ion immobilized at a chromatography solid phase surface.

27. A method as in any of claims 21-26, wherein L is histaminy purine and n is six.

10

28. A method as in any of claims 21-27, wherein  $N_y$  is DNA.

29. A method as in either of claims 19 or 20, the allowing step involving allowing the first strand to be immobilized at the surface via a linkage  $R-Ch-M-L_n-N_y$ , wherein R represents the surface, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent,  $N_y$  represents the first strand, L represents a moiety that can coordinate a metal ion, n is at least one, and y is at least two.

30. A method as in claim 29, wherein R is a surface of gold sol or a surface of a chromatography solid phase.

31. A method as in claim 29, wherein R is a surface of a chromatography solid phase.

32. A method as in any of claims 29-31, wherein Ch and M are together selected such that the dissociation constant of the combination in aqueous solution is better than 10 nM at physiological pH.

33. A method as in any of claims 29-32, wherein Ch is nitrilotriacetic acid, 2,2'-bis (salicylideneamino)-6,6'-dimethyldiphenyl, or 1,8-bis (4-pyridyl)-3,6-dithiaoctane.

30

34. A method as in any of claims 29-33, wherein Ch is a quadridentate chelating agent.

35. A method as in claim 34, wherein Ch is nitrilotriacetic acid.

36. A method as in any of claims 29-35, wherein Ch and M are together selected such that the chelating agent coordinates all but at least two of the metal coordination sites.

5

37. A method as in any of claims 29-36, wherein Ch is a tetracntate chclating agent, and M has a coordination number of six.

38. A method as in any of claims 29-37, wherein M is  $\text{Ni}^{2+}$ .

10

39. A species comprising a single-stranded oligonucleotide immobilized on a surface and free of hybridization to any complimentary strand that is also immobilized on the surface to the extent that the complimentary strand cannot be removed under conditions that cause denaturation of oligonucleotide strand from its complimentary strand, the single-stranded  
15 oligonucleotide being immobilized via linkage able to withstand conditions harsher than 2 molar urea.

40. A species as in claim 39, wherein the single-stranded oligonucleotide is immobilized via incorporation into a species having a formula  $\text{L}_n\text{-N}_y$ , where  $\text{N}_y$  represents the oligonucleotide, L represents a moiety that can coordinate a metal ion, n is at least one, and y is least one,  $\text{L}_n$  has a  
20 generalized formula:



25

where Z is an organic moiety and Y is a ligand having the ability to coordinate a metal ion, Z and Y together allowing incorporation of  $\text{L}_n$  into or on an oligonucleotide sequence.

30 41. A species as in claim 40, wherein L is histaminyIpurine and n is six.

42. A species as in any of claims 39-41, wherein the single-stranded oligonucleotide is single-stranded DNA.

43. A species as in any of claims 39-42, wherein the single-stranded oligonucleotide is part of a species having a formula  $R\text{-Ch-M-L}_n\text{-N}_y$ , wherein R represents a chemical or physical moiety, Ch represents a chelating agent that can coordinate a metal ion, M represents a metal ion coordinated by the chelating agent,  $N_y$  represents the single-stranded oligonucleotide, L represents a moiety can coordinate a metal ion, and n is at least 2, and y is at least one.

44. A species as in claim 43, wherein R is a chromatography solid phase.

1/2




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/2




FIG. 2




FIG. 3

SUBSTITUTE SHEET (RULE 26)

FILE



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07H 21/00, 1/08, 19/04,</b> <b>C12Q 1/68, G01N 33/543</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/00435</b>  <b>(43) International Publication Date:</b> <b>8 January 1998 (08.01.98)</b>
<b>(21) International Application Number:</b> <b>PCT/US97/11496</b>  <b>(22) International Filing Date:</b> <b>30 June 1997 (30.06.97)</b>  <b>(30) Priority Data:</b> <b>60/021,195                      3 July 1996 (03.07.96)                      US</b>  <b>(71) Applicant (for all designated States except US):</b> <b>PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US];</b> <b>University Place, 124 Mount Auburn Street, Cambridge,</b> <b>MA 02138-5701 (US).</b>  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> <b>VERDINE, Gregory, L. [US/US]; 91 Outlook Drive, Lexington, MA 02173 (US).</b> <b>MIN, Changhee [KR/KR]; Doongji Apartment 109-1404,</b> <b>Doonsan Dong, Suh Ku, Daejon 302-173 (KR).</b>  <b>(74) Agent:</b> <b>OYER, Timothy, J.; Wolf, Greenfield &amp; Sacks, P.C.,</b> <b>600 Atlantic Avenue, Boston, MA 02210 (US).</b>		<b>(81) Designated States:</b> <b>AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> <b>7 May 1998 (07.05.98)</b>
<b>(54) Title:</b> <b>OLIGONUCLEOTIDE LINKER AND TECHNIQUES INVOLVING IMMOBILIZED AND LINKED OLIGONUCLEOTIDES</b>  <b>(57) Abstract</b>  <p>A technique is provided for linking an oligonucleotide, such as a single strand of DNA, to another moiety or solid phase. An oligonucleotide is provided with a linking functionality that can be defined by six neighboring hystaminyal purines, which can be coordinated to a metal ion that also is coordinated by a chelating linked to a solid phase or other moiety. The invention finds particular use in resolution of one strand of DNA from its complement by providing the first strand with the linking functionality and passing the DNA across a metal affinity chromatography solid phase.</p>		



*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	KE	Kenya	NL	Netherlands	VN	Viet Nam
CG	Congo	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CH	Switzerland	KP	Democratic People's Republic of Korea	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KR	Republic of Korea	PL	Poland		
CM	Cameroon	KZ	Kazakhstan	PT	Portugal		
CN	China	LC	Saint Lucia	RO	Romania		
CU	Cuba	LI	Liechtenstein	RU	Russian Federation		
CZ	Czech Republic	LK	Sri Lanka	SD	Sudan		
DE	Germany	LR	Liberia	SE	Sweden		
DK	Denmark			SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 97/11496

## A CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07H21/00 C07H1/08 C07H19/04 C12Q1/68 G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

## B FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Classification of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 497 585 A (L.D.ANDERSON ET AL.) 5 August 1992	1-6,8,9
Y	see claims 1,3 see page 4, line 48 ---	1-44
X	US 5 453 356 A (A.J.BARD ET AL) 26 September 1995	1,8
Y	see claims 1,16,18-23,30 ---	1-44
X	WO 90 00622 A (WALLACOF; PHARMACIA AB) 25 January 1990 see the whole document ---	1-3,5,8
X	EP 0 285 057 A (ENZO BIOCHEM INC.) 5 October 1988 see the whole document ---	1-3,5,8
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "B" document member of the same patent family

Date of the actual completion of the international search

2 March 1998

Date of mailing of the international search report

11/03/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 97/11496

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 14841 A (BAXTER DIAGNOSTICS INC.) 3 September 1992 see the whole document ---	1-3,5,8
X	US 5 256 535 A (J.YLIKOSKI ET AL.) 26 October 1993 see column 19 - column 20; claims 1-9 ---	1-3,8
X	US 4 952 685 A (J.G.STAVRIANOPOULOS ) 28 August 1990 see abstract; table 1 ---	1,5
X	US 5 175 269 A (J.G.STAVRIANOPOULOS) 29 December 1992 see the whole document, but especially columns 12 and 32, example 6, and claims 1-6 ---	1,5
X	WO 96 02274 A (SCHERING AG ;NEXSTAR PHARMACEUTICALS INC (US)) 1 February 1996 see the whole document ---	1,8
X	US 5 238 808 A (BARD ALLEN J ET AL) 24 August 1993 see claims 1-11 ---	1,8
X	EP 0 340 675 A (PERKIN ELMER CORP) 8 November 1989 see claims 1-21 ---	1,8
X	WO 96 07668 A (CIBA GEIGY AG ;HAENER ROBERT (CH); HALL JONATHAN (CH); HUESKEN DIE) 14 March 1996 see abstract ---	1
X	EP 0 212 951 A (INTEGRATED GENETICS INC) 4 March 1987 see claims 5-12 ---	1
Y	GB 2 284 208 A (PNA DIAGNOSTICS AS) 31 May 1995 see the whole document, but especially page 7, line 20 to page 9, line 30 ---	1-44
Y	US 5 250 188 A (BRUENING RONALD L ET AL) 5 October 1993 see the whole document ---	1-44
Y	PORATH J: "IMAC-IMMOBILIZED METAL ION AFFINITY BASED CHROMATOGRAPHY" TRAC, TRENDS IN ANALYTICAL CHEMISTRY, AMSTERDAM, NL, vol. 7, no. 7, August 1988, pages 254-259, XP000001799 see the whole document ---	1-44
	---	

-/--

# INTERNATIONAL SEARCH REPORT

In International Application No  
PCT/US 97/11496

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	C.MIN ET AL.: "Template Directed Interference of Footprinting of Protein-Adenine Contacts" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 26, 3 July 1996, US, pages 6116-6120, XP002057407 cited in the application see the whole document ---	1
A	US 5 294 369 A (SHIGEKAWA BRIAN L ET AL) 15 March 1994 see claims 1-15 ---	10
A	EP 0 519 250 A (MILES INC.) 23 December 1992 see abstract ---	10
P,X	C.MIN ET AL.: "Immobilized Metal Affinity Chromatography of DNA" NUCLEIC ACIDS RESEARCH., vol. 24, no. 19, 1 October 1996, OXFORD GB, pages 3806-10, XP002057408 cited in the application see the whole document ---	1-44
P,X	US 5 620 850 A (C.C.BAMDAD ET AL.) 15 April 1997 cited in the application see the whole document -----	1-44

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 497585 A	05-08-92	AU 652021 8	11-08-94
		AU 1054592 A	06-08-92
		AU 1365292 A	07-09-92
		CA 2060235 A	31-07-92
		JP 6157600 A	03-06-94
		NZ 241444 A	27-02-96
		WO 9213965 A	20-08-92
		US 5439829 A	08-08-95
		ZA 9200617 A	29-07-93
-----			
US 5453356 A	26-09-95	AU 5020085 A	15-05-86
		DE 3587793 D	11-05-94
		DE 3587793 T	18-08-94
		EP 0199804 A	05-11-86
		EP 0580979 A	02-02-94
		JP 9110890 A	28-04-97
		JP 7173185 A	11-07-95
		JP 6065271 A	08-03-94
		JP 8026054 B	13-03-96
		JP 62500663 T	19-03-87
		WO 8602734 A	09-05-86
		US 5714089 A	03-02-98
		US 5221605 A	22-06-93
		US 5238808 A	24-08-93
		US 5310687 A	10-05-94
-----			
WO 9000622 A	25-01-90	EP 0378652 A	25-07-90
		JP 3500248 T	24-01-91
-----			
EP 285057 A	05-10-88	AT 119164 T	15-03-95
		AU 585199 B	15-06-89
		AU 1617983 A	05-01-84
		AU 4149389 A	04-01-90
		CA 1223831 A	07-07-87
		DE 3382626 A	12-11-92
		DE 3382782 D	06-04-95
		DE 3382782 T	19-10-95
		DK 130684 A	29-02-84
		DK 130784 A	29-02-84
		DK 291183 A	24-12-83

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 285057 A		EP 0097373 A	04-01-84
		EP 0285058 A	05-10-88
		EP 0286898 A	19-10-88
		EP 0285950 A	12-10-88
		EP 0302175 A	08-02-89
		EP 0618228 A	05-10-94
		JP 2625095 B	25-06-97
		JP 59062600 A	10-04-84
		JP 6234787 A	23-08-94
		US 5241060 A	31-08-93
		US 5260433 A	09-11-93
WO 9214841 A	03-09-92	AT 156522 T	15-08-97
		AU 653012 B	15-09-94
		AU 1450792 A	15-09-92
		CA 2079448 A	15-08-92
		OE 69221404 D	11-09-97
		OE 69221404 T	05-02-98
		EP 0525181 A	03-02-93
		JP 5505201 T	05-08-93
		JP 6057717 B	03-08-94
US 5256535 A	26-10-93	SE 454781 B	30-05-88
		OE 3784058 A	18-03-93
		EP 0288513 A	02-11-88
		JP 1501681 T	15-06-89
		SE 8604436 A	18-04-88
		WO 8802784 A	21-04-88
US 4952685 A	28-08-90	US 4707440 A	17-11-87
		US 5002885 A	26-03-91
		US 5013831 A	07-05-91
		US 5175269 A	29-12-92
		AU 581577 B	23-02-89
		AU 3821285 A	29-08-85
		CA 1314503 A	16-03-93
		DK 39885 A	31-07-85
		EP 0154788 A	18-09-85
		EP 0810435 A	03-12-97
		JP 2110469 C	21-11-96

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4952685 A		JP 8000800 B	10-01-96
		JP 60197645 A	07-10-85
		US 4843122 A	27-06-89
		US 4849505 A	18-07-89
		US 4849208 A	18-07-89
		US 4943523 A	24-07-90
<hr/>			
US 5175269 A	29-12-92	US 4952685 A	28-08-90
		US 5013831 A	07-05-91
		US 4707440 A	17-11-87
		US 5002885 A	26-03-91
		AU 581577 B	23-02-89
		AU 3821285 A	29-08-85
		CA 1314503 A	16-03-93
		DK 39885 A	31-07-85
		EP 0154788 A	18-09-85
		EP 0810435 A	03-12-97
		JP 2110469 C	21-11-96
		JP 8000800 B	10-01-96
		JP 60197645 A	07-10-85
		US 4843122 A	27-06-89
		US 4849505 A	18-07-89
		US 4849208 A	18-07-89
		US 4943523 A	24-07-90
<hr/>			
WO 9602274 A	01-02-96	DE 4424922 A	18-01-96
		DE 4445078 A	13-06-96
		AU 2979195 A	16-02-96
		EP 0777498 A	11-06-97
		HU 76329 A	28-08-97
		NO 970141 A	14-03-97
		PL 318147 A	12-05-97
		SK 2897 A	10-09-97
		ZA 9505895 A	19-02-96
<hr/>			
US 5238808 A	24-08-93	AU 5020085 A	15-05-86
		DE 3587793 D	11-05-94
		DE 3587793 T	18-08-94
		EP 0199804 A	05-11-86
		EP 0580979 A	02-02-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5238808 A		JP 9110890 A	28-04-97
		JP 7173185 A	11-07-95
		JP 6065271 A	08-03-94
		JP 8026054 8	13-03-96
		JP 62500663 T	19-03-87
		WO 8602734 A	09-05-86
		US 5714089 A	03-02-98
		US 5310687 A	10-05-94
		US 5453356 A	26-09-95
		US 5221605 A	22-06-93
EP 0340675 A	08-11-89	US 4962045 A	09-10-90
		CA 1330030 A	07-06-94
		DE 68923035 D	20-07-95
		DE 68923035 T	19-10-95
		JP 2017445 A	22-01-90
WO 9607668 A	14-03-96	AU 3474495 A	27-03-96
		CA 2197788 A	14-03-96
		EP 0778844 A	18-06-97
		FI 970740 A	21-02-97
		NO 970886 A	25-04-97
EP 0212951 A	04-03-87	DE 3689019 D	21-10-93
		DE 3689019 T	05-05-94
		JP 2509574 8	19-06-96
		JP 62039598 A	20-02-87
		US 5155216 A	13-10-92
GB 2284208 A	31-05-95	AU 684118 8	04-12-97
		AU 1107595 A	13-06-95
		CA 2176745 A	01-06-95
		WO 9514708 A	01-06-95
		EP 0730602 A	11-09-96
		JP 9504050 T	22-04-97
		ZA 9409317 A	24-05-96
US 5250188 A	05-10-93	NONE	
US 5294369 A	15-03-94	AT 142341 T	15-09-96



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/11496

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5294369 A		CA 2056843 A DE 69121849 D DE 69121849 T EP 0489465 A ES 2095291 T IE 75725 B JP 6116602 A US 5384073 A	06-06-92 10-10-96 06-02-97 10-06-92 16-02-97 24-09-97 26-04-94 24-01-95
EP 519250 A	23-12-92	CA 2070572 A JP 5188013 A	11-12-92 27-07-93
US 5620850 A	15-04-97	NONE	